Overall , intervention groups obtained higher 25(OH)D concentration than controls and there was obvious dose – response effect between intake dose and 25(OH)D concentration .
Baseline 25(OH)D concentration and age were significant indicators for 25(OH)D concentration .
Conclusions Regional- and age-specific recommended dosages of VitD supplements for population to achieve optimal 25(OH)D concentrations have been suggested
Background / Objectives Optimal doses of vitamin D ( VitD ) supplement in different population s are unclear .
We aim to evaluate the relationship between VitD supplementation and post-intervention serum 25-hydroxyvitamin D [ 25(OH)D ] concentration , to provide a recommended dosage of VitD for achieving an optimal 25(OH)D concentration for different population s .
Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: a randomized placebo-controlled trial.
OBJECTIVES Low vitamin D status has been shown to be associated with hypertension . We planned to research the effect of vitamin D and nifedipine in the treatment of patients with essential hypertension . METHODS Patients with grade s I-II essential hypertension were enrolled in this single-center , double-blind ,  placebo-controlled trial in Beijing . All patients received a conventional antihypertensive drug ( nifedipine , 30 mg/d ) . One hundred and twenty-six patients were r and omly assigned to receive vitamin D ( n=63 , 2000 IU/d ) or a placebo ( n=63 ) as an add-on to nifedipine , by the method of permutated block r and omization . Ambulatory blood pressure monitoring was performed at baseline ( month 0 ) , at month 3 and at month 6 . RESULTS In vitamin D supplementation group , there was a significant increase in mean 25-hydroxyvitamin D levels from baseline ( 19.4 ± 11.6 ng/ml ) to 6 months ( 34.1 ± 12.2 ng/ml ; p<0.001 ) . At 6 months , the primary end points , a difference in the fall of 24-h mean blood pressure , between the groups was -6.2 mmHg ( 95 % CI -11.2 ; -1.1 ) for systolic blood pressure ( p<0.001 ) and -4.2 mmHg ( 95 % CI -8.8 ; -0.3 ) for diastolic blood pressure ( p<0.001 ) under intention to treat analysis . In patients with vitamin D < 30 ng/ml at baseline ( n=113 ) , 24-h mean blood pressure decreased by 7.1/5.7 mmHg ( p<0.001 ) . Safety and tolerability were similar among the two groups . CONCLUSIONS Vitamin D supplementation can reduce blood pressure in patients with hypertension , it can be an adjuvant therapy for patients with grade s I-II essential hypertension . CLINICAL TRIAL REGISTRATION This study was registered in the Chinese Clinical Trial Registry , it is available in Website : http://www.chictr.org/cn/ ; REGISTRATION NUMBER ChiCTR-ONC-13003840
Overall , intervention groups obtained higher 25(OH)D concentration than controls and there was obvious dose – response effect between intake dose and 25(OH)D concentration .
Baseline 25(OH)D concentration and age were significant indicators for 25(OH)D concentration .
Conclusions Regional- and age-specific recommended dosages of VitD supplements for population to achieve optimal 25(OH)D concentrations have been suggested
Background / Objectives Optimal doses of vitamin D ( VitD ) supplement in different population s are unclear .
We aim to evaluate the relationship between VitD supplementation and post-intervention serum 25-hydroxyvitamin D [ 25(OH)D ] concentration , to provide a recommended dosage of VitD for achieving an optimal 25(OH)D concentration for different population s .